PEMBROLIZUMAB for Lung neoplasm malignant: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 3,575 adverse event reports in the FDA FAERS database where PEMBROLIZUMAB was used for Lung neoplasm malignant.
Most Reported Side Effects for PEMBROLIZUMAB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Malignant neoplasm progression | 10,111 | 12.1% | 5,124 | 3,426 |
| Death | 4,744 | 5.7% | 4,737 | 893 |
| Diarrhoea | 4,251 | 5.1% | 556 | 2,141 |
| Fatigue | 3,833 | 4.6% | 365 | 1,246 |
| Off label use | 3,416 | 4.1% | 747 | 1,045 |
| Product use in unapproved indication | 3,191 | 3.8% | 514 | 909 |
| Pyrexia | 3,155 | 3.8% | 444 | 2,194 |
| Rash | 2,900 | 3.5% | 289 | 1,047 |
| Nausea | 2,670 | 3.2% | 335 | 1,237 |
| Decreased appetite | 2,486 | 3.0% | 371 | 1,235 |
| Hypothyroidism | 2,326 | 2.8% | 242 | 935 |
| Product use issue | 2,323 | 2.8% | 417 | 610 |
| Hypertension | 2,245 | 2.7% | 276 | 1,118 |
| Asthenia | 2,131 | 2.5% | 300 | 1,058 |
| Interstitial lung disease | 2,113 | 2.5% | 869 | 1,276 |
Other Indications for PEMBROLIZUMAB
Non-small cell lung cancer (6,893)
Triple negative breast cancer (5,148)
Endometrial cancer (4,343)
Lung adenocarcinoma (3,954)
Malignant melanoma (3,261)
Renal cell carcinoma (3,027)
Metastatic malignant melanoma (2,742)
Uterine cancer (2,223)
Product used for unknown indication (2,091)
Transitional cell carcinoma (1,951)
Other Drugs Used for Lung neoplasm malignant
ERLOTINIB (9,207)
OSIMERTINIB (4,754)
NIVOLUMAB (4,197)
CARBOPLATIN (3,487)
ALECTINIB (2,932)
PEMETREXED (2,422)
CRIZOTINIB (1,949)
BEVACIZUMAB (1,810)
PACLITAXEL (1,747)
ATEZOLIZUMAB (1,262)